(VIANEWS) – Catalyst Pharmaceuticals (CPRX), ESCO Technologies (ESE), Iron Mountain Incorporated (IRM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalyst Pharmaceuticals (CPRX)
70.9% sales growth and 37.49% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $1.02.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 12.6. Meaning, the purchaser of the share is investing $12.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.49%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 120% and 118.2%, respectively.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $12.85 at 11:22 EST, way below its 52-week high of $22.11 and way above its 52-week low of $11.09.
Revenue Growth
Year-on-year quarterly revenue growth grew by 87.5%, now sitting on 302.95M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Catalyst Pharmaceuticals’s EBITDA is 23.29.
2. ESCO Technologies (ESE)
18.6% sales growth and 8.57% return on equity
ESCO Technologies Inc. produces and supplies engineered products and systems for industrial and commercial markets worldwide. It operates through Aerospace & Defense, Utility Solutions Group, and RF Shielding and Test segments. The Aerospace & Defense segment designs and manufactures filtration products, including hydraulic filter elements and fluid control devices used in commercial aerospace applications; filter mechanisms used in micro-propulsion devices for satellites; and custom designed filters for manned aircraft and submarines. It also designs, develops, and manufactures elastomeric-based signature reduction solutions for U.S. naval vessels; and mission-critical bushings, pins, sleeves, and precision-tolerance machined components for landing gear, rotor heads, engine mounts, flight controls, and actuation systems for the aerospace and defense industries. The Utility Solutions Group segment provides diagnostic testing solutions that enable electric power grid operators to assess the integrity of high-voltage power delivery equipment; and decision support tools for the renewable energy industry, primarily wind and solar. The RF Shielding and Test segment designs and manufactures RF test and secure communication facilities, acoustic test enclosures, RF and magnetically shielded rooms, RF measurement systems, and broadcast and recording studios; and RF absorptive materials and filters, active compensation systems, antennas, antenna masts, turntables, electric and magnetic probes, RF test cells, proprietary measurement software, and other test accessories to perform various tests. It also provides services, such as calibration for antennas and field probes, chamber certification, field surveys, customer training, and various product tests. The company distributes its products through a network of distributors, sales representatives, direct sales teams, and in-house sales personnel. The company was incorporated in 1990 and is based in St. Louis, Missouri.
Earnings Per Share
As for profitability, ESCO Technologies has a trailing twelve months EPS of $3.53.
PE Ratio
ESCO Technologies has a trailing twelve months price to earnings ratio of 30.32. Meaning, the purchaser of the share is investing $30.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.57%.
3. Iron Mountain Incorporated (IRM)
14.2% sales growth and 60.86% return on equity
Iron Mountain Incorporated (NYSE: IRM), founded in 1951, is the global leader for storage and information management services. Trusted by more than 225,000 organizations around the world, and with a real estate network of more than 90 million square feet across more than 1,480 facilities in approximately 50 countries, Iron Mountain stores and protects billions of valued assets, including critical business information, highly sensitive data, and cultural and historical artifacts. Providing solutions that include secure records storage, information management, digital transformation, secure destruction, as well as data centers, cloud services and art storage and logistics, Iron Mountain helps customers lower cost and risk, comply with regulations, recover from disaster, and enable a more digital way of working.
Earnings Per Share
As for profitability, Iron Mountain Incorporated has a trailing twelve months EPS of $1.29.
PE Ratio
Iron Mountain Incorporated has a trailing twelve months price to earnings ratio of 46.26. Meaning, the purchaser of the share is investing $46.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.86%.
4. Humana (HUM)
13.7% sales growth and 20.8% return on equity
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Humana has a trailing twelve months EPS of $26.85.
PE Ratio
Humana has a trailing twelve months price to earnings ratio of 19.45. Meaning, the purchaser of the share is investing $19.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.8%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4.1% and 74.1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13%, now sitting on 98.73B for the twelve trailing months.
Volume
Today’s last reported volume for Humana is 315701 which is 69.44% below its average volume of 1033100.
Previous days news about Humana(HUM)
- Humana (hum) sees a more significant dip than broader market: some facts to know. According to Zacks on Monday, 23 October, "Market participants will be closely following the financial results of Humana in its upcoming release. ", "Any recent changes to analyst estimates for Humana should also be noted by investors. "
5. Entergy Louisiana, LLC First Mortgage Bonds, 5.875% (ELA)
13.2% sales growth and 32.75% return on equity
Envela Corporation, together with its subsidiaries, primarily buys and sells jewelry and bullion products to individual consumers, dealers, Fortune 500 companies, municipalities, school districts, and other organizations in the United States. It offers jewelry and fine-watch products, including bridal jewelry, fashion jewelry, custom-made jewelry, diamonds, and other gemstones, as well as watches and jewelry components. The company also buys and sells various forms of gold, silver, platinum, and palladium products, including United States and other government coins, private mint medallions, art bars, and trade unit bars; and numismatic items, such as rare coins, currency, medals, tokens, and other collectibles, as well as provides jewelry and watches repair services. In addition, it offers end-of-life electronics recycling services; disposal transportation and product tracking services; IT-asset disposition services, including compliance and data sanitization services; and services to companies in the areas of software upgrades, and hardware or networking capabilities, as well as moving to cloud services. As of December 31, 2021, Envela Corporation marketed its products and services through six retail locations under the Dallas Gold & Silver Exchange name; and one retail location under the Charleston Gold & Diamond Exchange name, as well as through cgdeinc.com, dgse.com, echoenvironmental.com, ITADUSA.com, availrecovery.com, and teladvance.com e-commerce sites. The company was formerly known as DGSE Companies, Inc. and changed its name to Envela Corporation in December 2019. Envela Corporation was incorporated in 1965 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months EPS of $0.49.
PE Ratio
Entergy Louisiana, LLC First Mortgage Bonds, 5.875% has a trailing twelve months price to earnings ratio of 9.02. Meaning, the purchaser of the share is investing $9.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.75%.
6. Royalty Pharma (RPRX)
10.8% sales growth and 4.66% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $0.55.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 49.71. Meaning, the purchaser of the share is investing $49.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.66%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 2.36B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 6.9% and a drop 39.7% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 15, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 2.89%.
Sales Growth
Royalty Pharma’s sales growth is 4.7% for the current quarter and 10.8% for the next.
Previous days news about Royalty Pharma(RPRX)
- According to Zacks on Wednesday, 25 October, "Another stock from the same industry, Royalty Pharma (RPRX Quick QuoteRPRX – Free Report) , has yet to report results for the quarter ended September 2023. "
7. Insperity (NSP)
7.8% sales growth and 221.38% return on equity
Insperity, Inc. engages in the provision of human resources (HR) and business solutions to improve business performance for small and medium-sized businesses. It offers its HR services through its Workforce Optimization and Workforce Synchronization solutions that include a range of human resources functions, such as payroll and employment administration, employee benefits, workers' compensation, government compliance, performance management, and training and development services. The company also provides Insperity Premier, a cloud-based human capital management platform that offers professional employer organization HR outsourcing solutions to its clients; people management services; and employer liability management services, as well as solutions for middle market. In addition, it offers MarketPlace, an e-commerce portal that offers a range of products and services; and Workforce Acceleration, a human capital management and payroll services solution; time and attendance; performance management; recruiting; employment screening; retirement; and insurance services. The company was formerly known as Administaff, Inc. and changed its name to Insperity, Inc. in March 2011. Insperity, Inc. was founded in 1986 and is headquartered in Kingwood, Texas.
Earnings Per Share
As for profitability, Insperity has a trailing twelve months EPS of $4.74.
PE Ratio
Insperity has a trailing twelve months price to earnings ratio of 20.72. Meaning, the purchaser of the share is investing $20.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 221.38%.
Moving Average
Insperity’s worth is under its 50-day moving average of $98.20 and way under its 200-day moving average of $112.73.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.7%, now sitting on 6.28B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Insperity’s EBITDA is 121.55.
Sales Growth
Insperity’s sales growth is 6.9% for the current quarter and 7.8% for the next.
8. CBOE Holdings (CBOE)
5.3% sales growth and 18.8% return on equity
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, Europe and Asia Pacific, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities. This segment also offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The Europe and Asia Pacific segment offers pan-European listed equities and derivatives transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, CBOE Holdings has a trailing twelve months EPS of $6.09.
PE Ratio
CBOE Holdings has a trailing twelve months price to earnings ratio of 26.61. Meaning, the purchaser of the share is investing $26.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.8%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 7.9%, now sitting on 3.89B for the twelve trailing months.
